Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company specializing in ocular therapies, announced participation in two virtual healthcare investor conferences in September 2021. The H.C. Wainwright 23rd Annual Global Investment Conference will feature a pre-recorded presentation available from September 13 at 7:00 a.m. ET. Additionally, the Cantor Global Healthcare Conference 2021 will have a presentation starting September 28 at 4:40 p.m. ET. Both events will allow for virtual one-on-one meetings. Archived recordings will be accessible on the company's website for at least 30 days.
Details
News Market Reaction – KALA
The recorded move for KALA in the trading session of this news was +0.61%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in September 2021:
H.C. Wainwright 23rd Annual Global Investment Conference
A pre-recorded presentation will be made available beginning Monday, September 13, 2021 at 7:00 a.m. ET.
Cantor Global Healthcare Conference 2021
A pre-recorded presentation will be made available beginning Tuesday, September 28, 2021 at 4:40 p.m. ET.
Management will also be available for virtual 1x1 meetings on the same day as each presentation.
To access the webcasts and subsequent archived recording of each presentation, please visit “Events” in the “Investors” section of the Kala website at http://kalarx.com. An archived replay of the presentations will be available on the Company’s website for at least 30 days following each event.
About Kala Pharmaceuticals, Inc.
Kala is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension)
Investor Contacts:
Jill Steier
jill.steier@kalarx.com
781-996-5252
Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.